Interstitial granulomatous dermatitis associated with darifenacin

Mason, H.R.; Swanson, J.K.; Ho, J.; Patton, T.J.

Journal of Drugs in Dermatology Jdd 7(9): 895-897

2008


ISSN/ISBN: 1545-9616
PMID: 19112808
Document Number: 13197
Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.

Document emailed within 1 workday
Secure & encrypted payments

Interstitial granulomatous dermatitis associated with darifenacin